Windtree Therapeutics Inc Stock News

Here's what you need to know about trading penny stocks on August 24th The post Popular Penny Stocks For Your Buy List Today? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Informat

Source: sfam_photo / Shutterstock.com Windtree Therapeutics (NASDAQ: WINT ) is one of the biggest stock movers on Tuesday after announcing a new global licensing agreement for AEROSURF. AEROSURF is th

Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock. Istar

Company to present on Monday, April 4, 2022 at 11:00 am Company to present on Monday, April 4, 2022 at 11:00 am

Windtree Therapeutics Inc (NASDAQ: WINT) announced results from its Phase 2 study of lucinactant (KL4 surfactant) for severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung

Windtree Therapeutics Inc (NASDAQ: WINT ) has completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure. The study enrolled 60 patients with severe heart failure and systolic blood pressure (SBP) between 75 and 90 mmHg. The study … Full story available on Benzinga.com

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time. To view the presentation, click Full story available on Benzinga.com

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for

Windtree Therapeutics Inc (NASDAQ: WINT ) has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 of 2022. The 20-subject Phase 2 trial Full story available on Benzinga.com

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated i

Windtree Therapeutics <> completed enrollment in its phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory

Windtree Therapeutics Inc (WINT) shares closed today at 1.5% above its 52 week low of $1.36, giving the company a market cap of $39M. The stock is currently down 14.0% year-to-date, down 74.3% over the past 12 months, and up 1.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 16.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 594.8% The company's stock price performance over the past 12 months lags the peer average by 165.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Windtree Therapeutics Inc (WINT) shares closed 1.4% lower than its previous 52 week low, giving the company a market cap of $40M. The stock is currently down 71.7% year-to-date, down 72.4% over the past 12 months, and up 10.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 55.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 143.7% The company's stock price performance over the past 12 months lags the peer average by 142.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Northern Trust Corp increased its position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) by 28.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 65,380 shares of the companys stock after buying an additional 14,637 shares during the quarter. Northern Trust Corps holdings in Windtree [] The post Northern Trust Corp Grows Position in Windtree Therapeutics, Inc. (NASDAQ:WINT) appeared first on ETF Daily News .